Abstract
Spinal cord injury (SCI) is a long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The underlying mechanisms responsible for the failure of axonal regeneration after SCI remain only partially understood. Although a spectrum of medical treatments has been made available for this disease, the therapeutic effects remain disappointing. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, we summarized the application of antibodies in SCI in studies of myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. In the meantime, the combination treatment of the antibody with other reagents or stem cell transplant was also reviewed.
Keywords: Antibody, spinal cord injury, neuroprotective, myelin repair, anti-immune reaction, neuropathic pain
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Therapeutic Antibodies for Spinal Cord Injury
Volume: 16 Issue: 1
Author(s): Dan-yang Tang and Wei-jiang Zhao
Affiliation:
Keywords: Antibody, spinal cord injury, neuroprotective, myelin repair, anti-immune reaction, neuropathic pain
Abstract: Spinal cord injury (SCI) is a long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The underlying mechanisms responsible for the failure of axonal regeneration after SCI remain only partially understood. Although a spectrum of medical treatments has been made available for this disease, the therapeutic effects remain disappointing. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, we summarized the application of antibodies in SCI in studies of myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. In the meantime, the combination treatment of the antibody with other reagents or stem cell transplant was also reviewed.
Export Options
About this article
Cite this article as:
Tang Dan-yang and Zhao Wei-jiang, Therapeutic Antibodies for Spinal Cord Injury, CNS & Neurological Disorders - Drug Targets 2017; 16 (1) . https://dx.doi.org/10.2174/1871527315666160915150754
DOI https://dx.doi.org/10.2174/1871527315666160915150754 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Evaluation of <sup>99m</sup>Technetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis
Current Medical Imaging P2X1 and P2X2 Receptors in the Central Nervous System as Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Mollusk-Derived Growth Factor and the New Subfamily of Adenosine Deaminase-related Growth Factors
Current Pharmaceutical Design Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Metabotropic Glutamate Receptors as Targets for Analgesia: Antagonism, Activation, and Allosteric Modulation
Current Pharmaceutical Biotechnology Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design The Role of STAT 3 in Tissue Fibrosis
Current Chemical Biology Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design